Inhibitors of lysine specific demethylase-1

Patent metadata

Field	Value
Publication number	US-9573930-B2
Application number	US-201614988022-A
Country	US
Kind code	B2
Filing date	Jan 5, 2016
Priority date	May 1, 2014
Publication date	Feb 21, 2017
Grant date	Feb 21, 2017

Abstract

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.

First claim

We claim:

1. A compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof,

wherein,
W is N, C—H, or C—F;
X is hydrogen, halogen, —CN, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted carbocyclylalkynyl, optionally substituted aryl, or optionally substituted heteroaryl;
Y is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted cycloalkylalkyl; and
Z is an optionally substituted group chosen from alkyl, carbocyclyl, C-attached heterocyclyl, N-attached heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, —O-heterocyclyl, —N(R)-heterocyclyl, —O-heterocyclylalkyl, —N(R)-heterocyclylalkyl, —N(R)(C 1 -C 4 alkylene)-NR 2 , or —O(C 1 -C 4 alkylene)-NR 2 ; wherein R is hydrogen or C 1 -C 4 alkyl.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein W is C—H, or C—F.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is hydrogen, halogen, or —CN.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is optionally substituted aryl.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Y is optionally substituted alkyl or optionally substituted cycloalkylalkyl.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is optionally substituted alkyl.

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is optionally substituted carbocyclyl.

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is optionally substituted C-attached heterocyclyl.

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is optionally substituted heterocyclylalkyl.

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is optionally substituted heterocyclylalkenyl.

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is optionally substituted —O-heterocyclyl.

12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is optionally substituted —N(R)-heterocyclyl, and wherein R is hydrogen or C 1 -C 4 alkyl.

13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is optionally substituted —N(R)-heterocyclylalkyl, and R is hydrogen or C 1 -C 4 alkyl.

14. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is optionally substituted —N(R)(C 1 -C 4 alkylene)-NR 2 , and R is hydrogen or C 1 -C 4 alkyl.

15. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is optionally substituted —O(C 1 -C 4 alkylene)-NR 2 , and R is hydrogen or C 1 -C 4 alkyl.

16. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

Assignees

• Quanticel Pharmaceuticals Inc
• Celgene Quanticel Res Inc

Inventors

• Chen Young K
• Kanouni Toufike
• Kaldor Stephen W
• Stafford Jeffrey Alan
• Veal James Marvin

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/02

  specific for leukemia · CPC title

• C07D403/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D401/14

  containing three or more hetero rings · CPC title